<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377024</url>
  </required_header>
  <id_info>
    <org_study_id>EBI_CT_TF</org_study_id>
    <nct_id>NCT02377024</nct_id>
  </id_info>
  <brief_title>Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions</brief_title>
  <official_title>Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions in Healthy Adults With Subjective Cognitive Impairment: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the cognitive enhancement effect and safety of
      Tremella Fuciformis, using the cognitive and clinical indicators (e.g. memory, attention, and
      psychomotor speed) and the latest brain imaging methods for healthy adults suffering
      subjective cognitive impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in neurocognitive function (neurocognitive test batteries such as CANTAB)</measure>
    <time_frame>baseline, 8th week</time_frame>
    <description>Scores from neurocognitive test batteries such as CANTAB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in brain structure analyzed using the computational approach</measure>
    <time_frame>baseline, 8th week</time_frame>
    <description>Morphometric analysis of brain structures in magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in brain function analyzed using the computational approach (Blood oxygenation level dependent (BOLD) signal intensity)</measure>
    <time_frame>baseline, 8 week</time_frame>
    <description>Blood oxygenation level dependent (BOLD) signal intensity and their connectivity assessed using functional magnetic resonance imaging scans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in brain biochemical metabolism analyzed using the computational approach (Brain metabolite concentrations assessed using magnetic resonance spectroscopy)</measure>
    <time_frame>baseline, 8th week</time_frame>
    <description>Brain metabolite concentrations assessed using magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Subjective Memory Complaints Questionnaire scores at 8th weeks</measure>
    <time_frame>baseline, 8th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>4th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>8th week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Healthy Adults With Subjective Memory Complaints</condition>
  <arm_group>
    <arm_group_label>TF 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TF 600mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TF 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TF 1200mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TF 600mg</intervention_name>
    <arm_group_label>TF 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TF 1200mg</intervention_name>
    <arm_group_label>TF 1200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 40 and 65 years old

          -  Global Deterioration Scale score (GDS) of 2

          -  High school or higher levels of education.

        Exclusion Criteria:

          -  Current pregnancy or breast-feeding

          -  Evidence of neurologic or medical conditions

          -  Axis I diagnosis when assessed by the board certified psychiatrist using the
             Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental
             Disorder, 4th edition (DSM-IV)(SCID-IV)

          -  Mini-mental status examination score of 24 or less

          -  Clinical Dementia Rating score of 0.5 or more suggesting cognitive impairment beyond
             self-perceived subjective deficits

          -  Intelligence quotient less than 70

          -  Contraindications to magnetic resonance imaging (MRI)

          -  Use of psychotropics in last 3 months

          -  Use of oral contraceptive medication

          -  Participation in other clinical trials during the study period that might affect the
             outcome of the present study

          -  Allergic adverse reactions to mushrooms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ewha Womans University</name>
      <address>
        <city>Seoul</city>
        <zip>120-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

